August 28th 2025
The authors examine common FDA 483 findings and outline strategies to address and prevent regulatory non-compliance.
J&J to Recall Select Lots of Prezista Due to Possible TBA Contamination
May 19th 2011Johnson & Johnson subsidiary Janssen-Cilag International reported that the company is working with regulatory authorities in five countries to address trace amounts of 2,4,6- tribromoanisole identified in five batches of the HIV/AIDS medicine Prezista.
Bisphosphonates, Approvals And Ongoing Studies At The EMA
April 22nd 2011The EMA has concluded a class review of bisphosphonates, adopted a number of positives opinions for new medicines and revealed more about the ongoing studies regarding GlaxoSmithKline's Pandemrix pandemic influenza vaccine and a possible link with narcolepsy.